MINDCURE Provides Update on Strategic Review Post published:March 16, 2022 Post category:Press Release
Nova Mentis Announces Closing of Non-Brokered Financing Post published:March 15, 2022 Post category:Press Release
Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT Post published:March 15, 2022 Post category:Press Release
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Post published:March 14, 2022 Post category:Press Release
Numinus Expands Natural Psychedelic Research with New Biosecurity License Post published:March 14, 2022 Post category:Press Release
Psychedelic Bulletin: Tensions Rise Among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum Post published:March 11, 2022 Post category:Psychedelic Bulletin
Red Light Holland and Advocacy Group Psychedelic Medicine Alliance Washington Celebrate the Success of their Collaboration as Washington Legislature Funds Psilocybin Wellness Workgroup Post published:March 11, 2022 Post category:Press Release
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets Post published:March 10, 2022 Post category:Press Release
Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange Post published:March 10, 2022 Post category:Press Release
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research Post published:March 9, 2022 Post category:Press Release